Inner Retinal Thinning After Brilliant Blue G-assisted Internal Limiting Membrane Peeling for Vitreoretinal Interface Disorders
Overview
Affiliations
The aim of this study was to evaluate ganglion cell layer and nerve fiber layer thickness after Brilliant Blue G (BBG)-assisted internal limiting membrane (ILM) peeling for vitreomacular disorders. Retrospective analysis of spectral domain optical coherence tomography (SD-OCT) of 42 eyes of 42 patients, who underwent pars plana vitrectomy with BBG-assisted ILM peeling, was performed. Inclusion criteria were idiopathic macular hole, idiopathic vitreomacular traction, and idiopathic epiretinal membrane. Key exclusion criteria were vitreoretinal interface abnormalities secondary to any other diseases, follow-up period of less than 3 months, and any other associated retinal pathology. Average, minimum, and sectoral ganglion cell, and inner plexiform layers (GCIPL) and retinal nerve fiber layer (RNFL) parameters were collected. Changes in these parameters from baseline to 3- and 6-month visits after surgery were analyzed. At 3 months after surgery, we found a statistically significant reduction in the average GCIPL thickness (P = 0.031) and also in the superior sectors (P < 0.05) compared to the baseline values. A similar reduction was observed in the minimum RNFL thickness (P = 0.028) as well as in the superior sectoral RNFL thickness (P < 0.05). In 14 eyes with 6 months of follow-up, a similar statistically significant thinning of the GCIPL and RNFL was observed. However, the difference between the 3-month and 6-month values was not statistically significant (P = 0.679). BBG-assisted ILM peeling for vitreomacular interface disorders leads to thinning of the inner retina including GCIPL and RNFL. These structural changes should be correlated with retinal function tests to explore the pros and cons of this surgical step.
Outcomes of vitreoretinal surgery in eyes with retinitis pigmentosa without retinal detachment.
Upadhyaya A, Kiri H, Natarajan R, Hansraj S, Padhy S, Takkar B Graefes Arch Clin Exp Ophthalmol. 2023; 262(2):441-448.
PMID: 37861848 DOI: 10.1007/s00417-023-06274-z.
Tao M, Wang G, Gou Y, Zhang M J Ophthalmol. 2022; 2022:4922616.
PMID: 36237559 PMC: 9553370. DOI: 10.1155/2022/4922616.
Torres-Villaros H, Louis-Philippe S, Amari F, Giocanti-Auregan A, Janicot L Am J Ophthalmol Case Rep. 2022; 27:101588.
PMID: 35637750 PMC: 9142655. DOI: 10.1016/j.ajoc.2022.101588.
Valera-Cornejo D, Garcia-Roa M, Ramirez-Neria P, Romero-Morales V, Garcia-Franco R Arq Bras Oftalmol. 2021; 85(2):120-127.
PMID: 34431895 PMC: 11826577. DOI: 10.5935/0004-2749.20220020.
Li S, Li M, You R, Wang H, Zhao L, Wang Y Int Ophthalmol. 2021; 41(3):1129-1140.
PMID: 33392941 DOI: 10.1007/s10792-020-01656-2.